Estimated prevalence of stomach pathology in Hp-negative participants was higher in Alaska Native patients than CANHelp project participants, respectively: 18 and 3% for active gastritis; 69 and 14% for chronic gastritis; and 10 and 6% for intestinal metaplasia [40]. This evidence concerns the gene HP and chronic gastritis.